IL327995A - טיפול במולקולות חלבון קושר ליפידים - Google Patents
טיפול במולקולות חלבון קושר ליפידיםInfo
- Publication number
- IL327995A IL327995A IL327995A IL32799524A IL327995A IL 327995 A IL327995 A IL 327995A IL 327995 A IL327995 A IL 327995A IL 32799524 A IL32799524 A IL 32799524A IL 327995 A IL327995 A IL 327995A
- Authority
- IL
- Israel
- Prior art keywords
- lipid
- treatment
- binding protein
- protein molecules
- molecules
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363594669P | 2023-10-31 | 2023-10-31 | |
| PCT/IB2024/000624 WO2025093929A1 (en) | 2023-10-31 | 2024-10-30 | Lipid binding protein molecule therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL327995A true IL327995A (he) | 2026-06-01 |
Family
ID=93893740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL327995A IL327995A (he) | 2023-10-31 | 2024-10-30 | טיפול במולקולות חלבון קושר ליפידים |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR20260110167A (he) |
| CN (1) | CN122459685A (he) |
| AU (1) | AU2024370626A1 (he) |
| IL (1) | IL327995A (he) |
| MX (1) | MX2026005148A (he) |
| WO (1) | WO2025093929A1 (he) |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5128318A (en) | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
| GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| EP0751961A1 (en) | 1994-03-22 | 1997-01-08 | Research Corporation Technologies, Inc. | Eating suppressant peptides |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| DK1290013T3 (da) | 2000-04-21 | 2006-06-26 | Amgen Inc | Apo-A1/All-peptidderivater |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| WO2002038609A2 (en) | 2000-11-10 | 2002-05-16 | Proteopharma Aps | Apolipoprotein conjugates |
| US7217785B2 (en) | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| ES2304452T3 (es) | 2001-08-20 | 2008-10-16 | Csl Behring Ag | Una hdl para el tratamiento de un ictus y de otras condiciones isquemicas. |
| US7223726B2 (en) | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| MXPA04011312A (es) | 2002-05-17 | 2005-02-14 | Esperion Therapeutics Inc | Metodo para el tratamiento de desordenes dislipidemicos. |
| US6953840B2 (en) | 2002-07-30 | 2005-10-11 | Esperion Therapeutics, Inc. | Methods of using non-human animal Apolipoprotein A-I protein |
| WO2004073684A2 (en) | 2003-02-14 | 2004-09-02 | Children's Hospital & Research Center At Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
| JP5048486B2 (ja) | 2004-07-16 | 2012-10-17 | トラスティーズ オブ タフツ カレッジ | アポリポタンパク質a1の模倣物とその使用 |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| BRPI0614966A2 (pt) | 2005-08-26 | 2016-09-13 | Cerenis Therapeutics Holding S A | vetor de expressão, bactéria de ácido lático, apolipoproteína isenta de endotoxina, e, método de produção de uma apolipoproteína isenta de endotoxina |
| US8541236B2 (en) | 2006-12-08 | 2013-09-24 | University Of Washington | Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls |
| WO2008104890A2 (en) | 2007-02-28 | 2008-09-04 | Cerenis Therapeutics Holding Sa | Compositions and methods for producing apolipoprotein |
| US9173890B2 (en) | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| ES2601830T3 (es) | 2007-10-23 | 2017-02-16 | The Cleveland Clinic Foundation | Apolipoproteína A-1 resistente a oxidantes y péptidos miméticos |
| MX2011008599A (es) | 2009-02-16 | 2011-11-18 | Cerenis Therapeutics Sa | Peptidos mimeticos de la apolipoproteina a-i. |
| WO2011143362A1 (en) | 2010-05-11 | 2011-11-17 | Esperion Therapeutics, Inc. | Dimeric oxidation-resistant apolipoprotein a1 variants |
| LT2673296T (lt) | 2011-02-07 | 2019-02-25 | Cerenis Therapeutics Holding Sa | Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai |
| US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| SG11201506456VA (en) | 2013-03-15 | 2015-09-29 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| RU2016144908A (ru) | 2014-05-02 | 2018-06-05 | Серени Терапеутикс Холдинг Са | Маркеры hdl-терапии |
| US20190046608A1 (en) | 2017-08-10 | 2019-02-14 | Cerenis Therapeutics Holding Sa | Apomers |
| TW201919712A (zh) | 2017-08-10 | 2019-06-01 | 法商塞勒尼斯醫療控股公司 | 運送子(cargomers) |
| CA3197168A1 (en) | 2020-10-01 | 2022-04-07 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
| IL317896A (he) | 2022-06-28 | 2025-02-01 | Abionyx Pharma Sa | תרכובות ותהליכים לסינתזה של ספינגומיאלינים |
-
2024
- 2024-10-30 IL IL327995A patent/IL327995A/he unknown
- 2024-10-30 WO PCT/IB2024/000624 patent/WO2025093929A1/en active Pending
- 2024-10-30 AU AU2024370626A patent/AU2024370626A1/en active Pending
- 2024-10-30 CN CN202480081923.6A patent/CN122459685A/zh active Pending
- 2024-10-30 KR KR1020267017210A patent/KR20260110167A/ko active Pending
-
2026
- 2026-04-28 MX MX2026005148A patent/MX2026005148A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2026005148A (es) | 2026-06-01 |
| KR20260110167A (ko) | 2026-07-14 |
| CN122459685A (zh) | 2026-07-24 |
| WO2025093929A1 (en) | 2025-05-08 |
| AU2024370626A1 (en) | 2026-05-14 |